Vaxcyte SVP Cowan Elvia forfeited 1,327 shares at $60.36 each, leaving 27,860 shares after the September 8 transaction. The forfeiture represented about 4.5% of Elvia’s prior Vaxcyte holding, giving investors a precise view of the resulting insider position and transaction scale.
Key Highlights
- The transaction used SEC code F.
- Cowan Elvia’s transaction was dated September 8, 2026.
- The forfeiture represented about 4.5% of Elvia’s prior shareholding.
Vaxcyte, Inc. (NASDAQ: PCVX) recorded a forfeiture of 1,327 shares held by Cowan Elvia at $60.36 per share. The transaction left Elvia with 27,860 shares.
$60.36 Share Forfeiture Dated September 8
The transaction took place on September 8, 2026. Its SEC transaction code was F. Cowan Elvia serves as Vaxcyte’s SVP, Finance & CAO. The reported action involved 1,327 Vaxcyte shares priced at $60.36 per share.
The forfeiture represented about 4.5% of Cowan Elvia’s prior Vaxcyte shareholding. Transaction code F denotes shares withheld or delivered to cover taxes or an exercise price.
FAQs
Q: How many Vaxcyte shares did Cowan Elvia forfeit?
A: Cowan Elvia forfeited 1,327 Vaxcyte shares at $60.36 per share. The transaction was dated September 8, 2026, and used SEC transaction code F.
Q: What was the impact of the Vaxcyte insider transaction?
A: The transaction left Cowan Elvia owning 27,860 Vaxcyte shares after the reported forfeiture. The 1,327 forfeited shares represented about 4.5% of her prior shareholding.
Q: What does code F mean in the Vaxcyte share transaction?
A: The source identifies SEC transaction code F for the reported forfeiture. It does not provide a further description of the code.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.